Diana Abdueva, PhD, states selecting the right therapy for rheumatoid arthritis is a complex challenge due to both the economic burden of therapies and the trial-and-error process patients often undergo.
New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.
The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.
Ryan DeMasi, MD, explained despite the patients' shorter disease duration, they exhibited severe symptoms, prompting a more aggressive early intervention approach using treatment with upadacitinib.
Patients with PsA in the self-reported racial and ethnic minority were less likely to be diagnosed within 12 months of symptom onset and were more frequently uninsured compared with White patients .